Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Mechler, Konstantin [VerfasserIn]   i
 Banaschewski, Tobias [VerfasserIn]   i
 Hohmann, Sarah [VerfasserIn]   i
 Häge, Alexander [VerfasserIn]   i
Titel:Evidence-based pharmacological treatment options for ADHD in children and adolescents
Verf.angabe:Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann, Alexander Häge
E-Jahr:2022
Jahr:February 2022
Umfang:11 S.
Fussnoten:Online verfügbar: 23. Juni 2021, Artikelversion: 3. Februar 2022 ; Gesehen am 14.05.2024
Titel Quelle:Enthalten in: The international journal of neuropsychopharmacology
Ort Quelle:Oxford : Oxford Univ. Press, 1998
Jahr Quelle:2022
Band/Heft Quelle:230(2022) vom: Feb., Artikel-ID 107940, Seite 1-11
ISSN Quelle:1469-5111
Abstract:Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. Its prevalence lies at approximately 5% in children and adolescents and at approximately 2.5% in adults. The disorder follows a multifactorial etiology and shows a high heritability. Patients show a high interindividual and intraindividual variability of symptoms, with executive deficits in several cognitive domains. Overall, ADHD is associated with high rates of psychiatric comorbidities, and insufficient treatment is linked to adverse long-term outcomes. Current clinical guidelines recommend an individualized multimodal treatment approach including psychoeducation, pharmacological interventions, and non-pharmacological interventions. Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine). While available pharmacological treatment options for ADHD show relatively large effect sizes (in short-term trials) and overall good tolerability, there is still a need for improvement of current pharmacotherapeutic strategies and for the development of novel medications. This review summarizes available pharmacological treatment options for ADHD in children and adolescents, identifies current issues in research and evidence gaps, and provides an overview of ongoing efforts to develop new medications for the treatment of ADHD in children and adolescents by means of a systematic cross-sectional analysis of the clinical trials registry www.clinicaltrials.gov.
DOI:doi:10.1016/j.pharmthera.2021.107940
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1016/j.pharmthera.2021.107940
 kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S016372582100142X
 DOI: https://doi.org/10.1016/j.pharmthera.2021.107940
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Amphetamines
 Atomoxetine
 Attention-deficit hyperactivity disorder
 Clonidine
 Guanfacine
 Methylphenidate
 Psychopharmacology
K10plus-PPN:1888458437
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69213294   QR-Code
zum Seitenanfang